Granuflo and NaturaLyte Cardiac Arrest and Death Claims Investigated by McSweeney / Langevin
The law firm McSweeney / Langevin is investigating legal claims on behalf of individuals and families harmed by Granuflo or NaturaLyte. McSweeney / Langevin's legal investigation follows the Food and Drug Administration's investigation into whether the nation's largest operator of dialysis centers violated federal regulations by failing to inform the public of a potentially lethal risk connected to Granuflo and NaturaLyte.
(PRWEB) November 01, 2012
Granuflo and NaturaLyte lawsuits are currently being investigated by the law firm McSweeney / Langevin.
Fresenius, the manufacturer of Granuflo and NaturaLyte conducted an internal study of the safety of Granuflo and NaturaLyte. The internal study revealed an up to eight-fold increase in the risk of cardiopulmonary arrest and sudden cardiac death. This information was detailed in a November 4, 2011 Internal Memo sent to medical directors and physicians. The internal memo warned a small number of doctors of the sharp increase of patients dying suddenly from cardiac arrest. The internal memo states "[t]his issue needs to be addressed urgently."
However, Fresenius did not address the issue "urgently." In fact, Fresenius failed to inform the Food and Drug Administration of dangers associated with Granuflo and NaturaLyte. According to the New York Times June 14, 2012 article entitled, Dialysis Company's Failure to Ward of Product Risk Draws Inquiry, Fresenius only warned the public of the safety risks and dangers of Granuflo and NaturaLyte when an individual sent an anonymous copy of the internal memo to the FDA.
Steve Silverman, director of compliance for the FD's medical device division, stated "[he] was troubled by the fact Fresenius on its own initiate didn't notify its entire customer base of its concerns."
On March 29, 2012, The FDA Issued a Class I recall of Granufo and NaturaLyte shortly after the anonymous tip. A Class I recall is the most serious recall due to the risk of serious injury and death.
According to the FDA's Class I Recall, side effects of Granuflo and NaturaLyte include cardiopulmonary arrest, heart problems, metabolic alkalosis, low blood pressure, sudden MI or heart attack, stroke and even death. These side effects are usually seen shortly after the dialysis treatment.
McSweeney / Langevin is offering free legal consultations to victims of Granuflo and NaturaLyte. Please visit our firm's site if you or a loved one has experienced cardiac arrest or sudden heart attack shortly after receiving dialysis with Granuflo or NaturaLyte. Feel free to contact an attorney at 1-800-888-4425 for a free legal consultation.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/11/prweb10079755.htmView Comments and Join the Discussion!